Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosiglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 12/20 | 1.00 |
| ▸ | RARG | P13631 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosiglitazone SCHEMBL504723 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL5734118 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL122053 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL29376790 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL466397 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL19469505 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL29757195 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL5556077 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL5735765 | 0.99 | PPARG (0.98) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL2118157 | 0.99 | PPARG (0.98) | PPARGRARGRXRAPPARAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11806 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564728-B2 | Treatment of central nervous system disorders | KNOW BIO, LLC (US) | 2026-03-03 | — | — | US | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250092360-A1 | METHODS AND COMPOSITIONS FOR GENERATING SOMATOSTATIN+ INTERNEURONS FROM HUMAN FOREBRAIN NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2025-03-20 | — | — | US | claimed |
| US-20240423967-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | ARES TRADING S.A. (CH) | 2024-12-26 | — | — | US | claimed |
| US-20240398905-A1 | COMPOSITIONS AND METHOD FOR ADMINISTERING PPARgamma AGONISTS, SURFACTANT PEPTIDES AND PHOSOPHOLIPIDS | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2024-12-05 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-12146156-B2 | Use of LRP2 agonists for generating myeloid-derived suppressor cells | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2024-11-19 | — | — | US | claimed |
| US-12083107-B2 | Pharmaceutical compositions comprising glitazones and Nrf2 activators | Kahrs, Bjoern Colin (CH) | 2024-09-10 | — | — | US | claimed |
| WO-2002013798-A2 | TREATMENT OF THE INSULIN RESISTANCE SYNDROME WITH SELECTIVE CGMP PDE5 INHIBITORS | PFIZER LIMITED (GB) | 2002-02-21 | — | — | WO | claimed |
| WO-2002013812-A1 | METHODS FOR TREATING INFLAMMATORY DISEASES | PERSHADSINGH HARRIHAR A (US) | 2002-02-21 | — | — | WO | claimed |
| EP-1180020-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | Acusphere, Inc. (US) | 2002-02-20 | — | — | EP | claimed |
| WO-2000072827-A9 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE INC (US) | 2002-01-31 | — | — | WO | claimed |
| WO-2002005785-A1 | MODULATED RELEASE THERAPEUTIC AEROSOLS | AEROPHARM TECHNOLOGY INCORPORATED (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2002004024-A1 | COMPOSITION FOR THE TREATMENT OF DIABETES | RIEVELEY ROBERT B (CA) | 2002-01-17 | — | — | WO | claimed |
| WO-2001082872-A2 | A MEDICINAL AEROSOL FORMULATION | AEROPHARM TECHNOLOGY, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| WO-2001082980-A1 | A MEDICINAL AEROSOL FORMULATION | AEROPHARM TECHNOLOGY, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |
| EP-0658161-B1 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1999-07-14 | — | — | EP | claimed |